Mefenamic Acid and Diclofenac Sodium in Osteoarthritis of the Weight Bearing Joints: A Double Blind Comparison

Aylward, Mansel; Maddock, J.; Lewis, Peter; Dewland, Peter

doi:10.1111/j.1742-1241.1985.tb07797.x

Cited by 6 publications

(1 citation statement)

References 9 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mefenamic acid, a drug used in the clinic for some 23 years for the management of mild to moderate pain, compares favourably with indomethacin 1 , sulindac 2 , diclofenac 3 and piroxicam 4 in the treatment of osteoarthritic pain. Mefenamic acid's analgesic efficacy also compares favourably with coproxamol 5 , diflunisal 6 and piroxicam 7 in the treatment of traumatic pain associated with soft tissue injuries or fractures.…”

Section: Introductionmentioning

confidence: 99%

Mefenamic acid versus ibuprofen in osteoarthritis — a double‐blind cross‐over study

Barnard-Jones¹,

Davies

Lalla³

et al. 1986

Int J Clinical Practice

View full text Add to dashboard Cite

One hundred and seventeen patients with osteoarthritis of the hip and/or knee were entered into this double-blind cross-over study of mefenamic acid and ibuprofen. Following a one week washout period, patients received either 1500 mg mefenamic acid or 1800 mg ibuprofen daily for four weeks. After a second, one-week washout period the patients were crossed over to the other active treatment for a further four weeks. Mefenamic acid was statistically significantly more effective in relieving pain at night of the affected joint. Of the 77 per cent of patients who expressed a preference for one or other of the medications, 64 per cent preferred mefenamic acid. Fifteen patients reported 19 adverse events while taking ibuprofen compared with only nine patients who reported 10 events while taking mefenamic acid.

show abstract

Section: Introductionmentioning

confidence: 99%

Mefenamic acid versus ibuprofen in osteoarthritis — a double‐blind cross‐over study

Barnard-Jones¹,

Davies

Lalla³

et al. 1986

Int J Clinical Practice

View full text Add to dashboard Cite

show abstract

Inclusion body myositis: clinical features and pathogenesis

2019

View full text Add to dashboard Cite

Mefenamic acid decreases inflammation but not joint lesions in experimental osteoarthritis

Aguiar

Queiroz-Junior

Sitta

et al. 2016

Int J Experimental Path

View full text Add to dashboard Cite

Mefenamic acid is a non-steroidal anti-inflammatory drug able to control the symptoms of osteoarthritis (OA), but its effects on protection of cartilage and bone are still unclear. This study aimed to investigate whether the control of inflammation by mefenamic acid translates into decreased joint lesions in experimental OA in rats. OA was induced by injecting 1 mg of monosodium iodoacetate (MIA) into the joints of rats. The animals were treated with mefenamic acid (50 mg/kg, daily, oral gavage) either pre-MIA injection (preventive) or post-MIA injection (therapeutic). Joint swelling and hyperalgesia were evaluated at baseline and 1, 3, 14 and 28 days after induction of OA. Intra-articular lavage and kinetics of cell migration into the synovium were measured 3 and 28 days after OA induction. Histopathological analysis, Osteoarthritis Research Society International (OARSI) score, total synovium cells count, cartilage area and levels of proteoglycans in joints were also evaluated. Mefenamic acid prevented joint oedema and hyperalgesia induced by MIA in the acute phase (3 days) of the disease. In the chronic phase (28 days), preventive and therapeutic regimens decreased the number of mononuclear cells in the joint cavity. In contrast, thickening of the synovium, bone resorption, loss of cartilage and levels of proteoglycans were unaffected by mefenamic acid when it was administered either preventively or therapeutically. Thus, mefenamic acid had anti-inflammatory effects but did not reduce the progression of OA lesions, thereby indicating that it is only effective for symptomatic control of OA.

show abstract

Mefenamic Acid and Diclofenac Sodium in Osteoarthritis of the Weight Bearing Joints: A Double Blind Comparison

Cited by 6 publications

References 9 publications

Mefenamic acid versus ibuprofen in osteoarthritis — a double‐blind cross‐over study

Mefenamic acid versus ibuprofen in osteoarthritis — a double‐blind cross‐over study

Inclusion body myositis: clinical features and pathogenesis

Mefenamic acid decreases inflammation but not joint lesions in experimental osteoarthritis

Contact Info

Product

Resources

About